This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A third look at the results from the HIMALAYA P3 trial of Imjudo(tremelimumab) in combination with Imfinzi and the novel STRIDE regimen in patients with unresectable hepatocellular carcinoma

Ticker(s): AZN

Who's the expert?

Institution: Oncology Hematology Associates of West Broward

  • treast 25 patients with HR+/HER2- metastatic breast cancer
  • comfortable discussing the Phase 3 results from the TROPiCS-02 study presented at ESMO

Interview Goal
see title.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.